Key result
Perioperative recombinant human erythropoietin reduced the mean number of blood transfusions required during colorectal surgery compared to placebo.
Why the study?
Does recombinant human erythropoietin improve perioperative hemoglobin concentration and reduce the need for blood transfusions in patients undergoing elective colorectal surgery with preoperative anemia?
RCT (n=100)
Double-blind
Does recombinant human erythropoietin improve perioperative hemoglobin concentration and reduce the need for blood transfusions in patients undergoing elective colorectal surgery with preoperative anemia?
Perioperative administration of recombinant human erythropoietin significantly increases hemoglobin concentrations and reduces the need for blood transfusions in patients undergoing elective colorectal surgery.
Answers are grounded in this paper and cite their sources.
Supports erythropoietin to minimize transfusions in anemic colorectal surgery patients; extends evidence for perioperative blood conservation.
In a double-blind placebo-controlled study we investigated the effect of recombinant human erythropoietin (r-HuEPO), on the perioperative hemoglobin concentration and the use of blood transfusions in patients undergoing elective colorectal surgery with a preoperative hemoglobin level </=8.5 mmol/L. Altogether 100 were included, and 81 patients could be evaluated. A total of 38 patients received r-HuEPO in a dose of 300 IU/kg body weight on day 4 before surgery and 150 IU/kg daily for the following 7 days; 43 patients received placebo. In addition, all patients received daily doses of 200 mg iron orally for 4 days before surgery. There were no differences between the two groups with regard to sex, height, weight, serum electrolytes, and liver function tests at study entry. The preentry hemoglobin concentration was similar in the two groups, with a median value of 7.9 (range 5.3-8.5) mmol/L in the erythropoietin group and 7.6 (5.1-8.5) mmol/L in the placebo group. On the day of surgery the median hemoglobin concentration was 7.8 (5. 3-9.2) mmol/L in the erythropoietin group and 7.2 (4.6-8.5) mmol/L in the placebo group (p < 0.05). On postoperative days 3 and 7 the values were 7.2 (5.3-8.2) and 7.5 (5.4-9.4) mmol/L, respectively, in the erythropoietin group compared to 6.7 (5.2-7.8) and 6.9 (5.1-8.6) mmol/L in the placebo group (p < 0.01). At discharge the hemoglobin concentration was 7.8 (5.9-8.8) mmol/L in the erythropoietin group and 7.2 (5.4-8.6) mmol/L in the placebo group (p < 0.002). The blood loss during operation was similar in the two groups. In the erythropoietin group the median value was 280 ml (range 25-2000 ml), with the lower and upper quartiles 150 and 500 ml, respectively. In the placebo group the blood loss was median 300 ml (range 50-1800 ml), with the lower and upper quartiles 200 and 750 ml, respectively. The number of blood transfusions given was significantly lower in the erythropoietin group, with a mean of 0.3 (range 0-6) units compared to 1.6 (0-9) units in the control group (p < 0.05). In conclusion, the hemoglobin concentration at the time of surgery and during the week following surgery was significantly higher in the group of patients receiving r-HuEPO perioperatively compared to the placebo group together with a significant lower use of blood transfusions in the r-HuEPO group. However, the clinical implications of these findings has yet to be proven.
No takes yet. Share an insight, caveat, or question.
Qvist et al. (1999) conducted an RCT in Elective colorectal surgery with preoperative anemia (n=100). Recombinant human erythropoietin (r-HuEPO) vs. Placebo plus 200 mg oral iron daily for 4 days before surgery was evaluated on Number of blood transfusions given (p=< 0.05). Perioperative recombinant human erythropoietin reduced the mean number of blood transfusions required during colorectal surgery compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: